Immuron Ltd (IMRN) stock
IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.87−0.03 (-3.20%)
Close on Nov 17, 2026Market cap $7.03MP/E –Yield –
Immuron r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was A$1.93M, down 46.3% from the year before. Over ten years it grew -6.1% a year on average. The highest annual figure on record is A$5.38M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$1.93M | -46.3% |
| FY2025 | Jun 30, 2025 | A$3.60M | -33.1% |
| FY2024 | Jun 30, 2024 | A$5.38M | +107.4% |
| FY2023 | Jun 30, 2023 | A$2.59M | +294.1% |
| FY2022 | Jun 30, 2022 | A$657.72K | -51.9% |
| FY2021 | Jun 30, 2021 | A$1.37M | +16.0% |
| FY2020 | Jun 30, 2020 | A$1.18M | +12.8% |
| FY2019 | Jun 30, 2019 | A$1.04M | -53.7% |
| FY2018 | Jun 30, 2018 | A$2.26M | -51.3% |
| FY2017 | Jun 30, 2017 | A$4.63M | +27.8% |
| FY2016 | Jun 30, 2016 | A$3.62M | – |
See a number that looks wrong?